Serum sCTLA-4 level is not associated with type 1 diabetes or the coexistence of autoantibodies in children and adolesce
- PDF / 786,054 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 52 Downloads / 192 Views
IGINAL RESEARCH
Autoimmunity Highlights Open Access
Serum sCTLA‑4 level is not associated with type 1 diabetes or the coexistence of autoantibodies in children and adolescent patients from the southern region of Saudi Arabia Ahmed Al‑Hakami*
Abstract Background: The soluble form of CTLA-4 (sCTLA-4) is associated with several autoimmune diseases. The aim of the study is to measure the serum sCTLA-4 levels in type I diabetic (T1DM) patients and to assess the presence of autoan‑ tibodies for a possible association. Methods: One hundred forty-two T1DM patients were enrolled in the study. Fifty of them were serologically positive for co-existing autoantibodies. One hundred and five subjects were enrolled in the study, as non-diabetic controls (1–17 years of age; median age—10 years). The serum samples of all the subjects were analyzed with ELISA to detect the concentration of sCTLA-4 and anti-GAD/IA2 IgG. Standard statistical analysis was conducted as required. Results: Ninety-four (66%) subjects of T1DM patients and five (4.7%) subjects of the non-diabetic group had anti‑ bodies positive for anti-GAD/IA2. Serum sCTLA-4 was low in most of the subjects of both the diabetic and control groups (p = 0.18). In the control group, nine individuals (8.6%) were positive for sCTLA-4. Similarly, only seven patients (4.9%) in the T1DM group had high levels of sCTLA-4, of which two were found to be double positive for anti-thyroid peroxidase and anti-thyroglobulin antibodies. In addition, among the T1DM patients, no significant relationships were observed between sCTLA-4 levels and age of onset (p = 0.43), disease duration (p = 0.09), or glycemic control (p = 0.32). Conclusion: Despite the previous findings of high sCTLA-4 levels in autoimmune diseases, serum levels of sCTLA-4 are not significantly different between T1DM patients and non-diabetic adolescents. Furthermore, we did not observe any association with autoantibody presence, glycemic control, or disease duration. Keywords: sCTLA-4, Type I diabetes (T1DM), Autoantibody coexistence
*Correspondence: [email protected]; [email protected] Department of Microbiology and Clinical Parasitology, College of Medicine, King Khalid University, P.O. Box 641, Abha 61421, Saudi Arabia
Background Type I diabetes (T1DM) is a chronic autoimmune condition characterized by progressive β-cell destruction and insufficient insulin production [1]. Similar to other autoimmune diseases, autoimmune reactivity in T1DM occurs as a result of multiple facets, including, genetic, environmental, and other aspects [2]. The presence of
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative C
Data Loading...
